CL2018003654A1 - Preparación de derivados del factor xa. - Google Patents

Preparación de derivados del factor xa.

Info

Publication number
CL2018003654A1
CL2018003654A1 CL2018003654A CL2018003654A CL2018003654A1 CL 2018003654 A1 CL2018003654 A1 CL 2018003654A1 CL 2018003654 A CL2018003654 A CL 2018003654A CL 2018003654 A CL2018003654 A CL 2018003654A CL 2018003654 A1 CL2018003654 A1 CL 2018003654A1
Authority
CL
Chile
Prior art keywords
protein
inhibitor
derivatives
factor
preparation
Prior art date
Application number
CL2018003654A
Other languages
English (en)
Spanish (es)
Inventor
Mark Karbarz
Pamela B Conley
Genmin Lu
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003654(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of CL2018003654A1 publication Critical patent/CL2018003654A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2018003654A 2016-06-17 2018-12-17 Preparación de derivados del factor xa. CL2018003654A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
CL2018003654A1 true CL2018003654A1 (es) 2019-01-25

Family

ID=60663351

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018003654A CL2018003654A1 (es) 2016-06-17 2018-12-17 Preparación de derivados del factor xa.
CL2020001733A CL2020001733A1 (es) 2016-06-17 2020-06-25 Una composición farmacéutica que comprende un portador farmacéuticamente aceptable y una parte de polipéptido de polipéptidos de dos cadenas. uso de la composición para revertir o inhibir la anticoagulación en un paciente que recibe un tratamiento de anticoagulación con un inhibidor del factor xa. (divisional solicitud 201803654).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020001733A CL2020001733A1 (es) 2016-06-17 2020-06-25 Una composición farmacéutica que comprende un portador farmacéuticamente aceptable y una parte de polipéptido de polipéptidos de dos cadenas. uso de la composición para revertir o inhibir la anticoagulación en un paciente que recibe un tratamiento de anticoagulación con un inhibidor del factor xa. (divisional solicitud 201803654).

Country Status (21)

Country Link
US (4) US10604748B2 (https=)
EP (3) EP4588932A3 (https=)
JP (4) JP6959268B2 (https=)
KR (1) KR102373215B1 (https=)
CN (3) CN110167575B (https=)
AU (2) AU2017283720C1 (https=)
CL (2) CL2018003654A1 (https=)
CO (1) CO2019000120A2 (https=)
DK (1) DK3472314T3 (https=)
EA (1) EA037815B1 (https=)
ES (2) ES3038834T3 (https=)
HU (1) HUE054597T2 (https=)
IL (1) IL263591B2 (https=)
MX (1) MX2018015873A (https=)
PE (1) PE20190661A1 (https=)
PH (1) PH12018502614A1 (https=)
PL (1) PL3472314T3 (https=)
PT (1) PT3472314T (https=)
SG (1) SG11201810915QA (https=)
SI (1) SI3472314T1 (https=)
WO (1) WO2017219034A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3604510T3 (pl) * 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
JP6959268B2 (ja) * 2016-06-17 2021-11-02 ポートラ ファーマシューティカルズ, インコーポレイテッド 第xa因子誘導体の調製
WO2019246094A1 (en) 2018-06-19 2019-12-26 Portola Pharmaceuticals, Inc. Antidotes to factor xa inhibitors
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) * 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
NZ592533A (en) 2005-11-08 2012-08-31 Millennium Pharm Inc METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Xa 저해제에 대한 안티도트 및 그것을 사용하는 방법
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) * 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
JP6261093B2 (ja) * 2012-06-14 2018-01-17 ポートラ ファーマシューティカルズ, インコーポレイテッド 組み換え第Xa因子誘導体の精製のための方法
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
SG10201705189XA (en) 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
MY173548A (en) * 2013-09-24 2020-02-04 Pfizer Fxa variant compositions
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
JP6959268B2 (ja) * 2016-06-17 2021-11-02 ポートラ ファーマシューティカルズ, インコーポレイテッド 第xa因子誘導体の調製

Also Published As

Publication number Publication date
EA201990052A1 (ru) 2019-05-31
US20170369862A1 (en) 2017-12-28
PE20190661A1 (es) 2019-05-08
SG11201810915QA (en) 2019-01-30
MX2018015873A (es) 2019-08-12
CN116425860B (zh) 2025-03-04
AU2023200825B2 (en) 2026-04-23
BR112018075964A2 (pt) 2019-04-02
US20240076642A1 (en) 2024-03-07
CA3027457A1 (en) 2017-12-21
EP3926044B1 (en) 2025-06-04
JP2019528242A (ja) 2019-10-10
CN110167575B (zh) 2024-03-15
WO2017219034A3 (en) 2019-03-14
IL263591B (en) 2022-11-01
EP4588932A3 (en) 2025-10-01
US20210348149A1 (en) 2021-11-11
US11845966B2 (en) 2023-12-19
CN118271391A (zh) 2024-07-02
AU2017283720B2 (en) 2022-11-17
HUE054597T2 (hu) 2021-09-28
CL2020001733A1 (es) 2020-09-25
WO2017219034A2 (en) 2017-12-21
US20200208131A1 (en) 2020-07-02
EA037815B1 (ru) 2021-05-25
JP6959268B2 (ja) 2021-11-02
PL3472314T3 (pl) 2021-11-22
IL263591B2 (en) 2023-03-01
JP2026010692A (ja) 2026-01-22
AU2017283720C1 (en) 2024-07-25
KR20190019134A (ko) 2019-02-26
AU2023200825A1 (en) 2023-03-16
EP3472314A2 (en) 2019-04-24
PH12018502614A1 (en) 2019-09-30
CO2019000120A2 (es) 2019-03-29
SI3472314T1 (sl) 2021-11-30
AU2017283720A1 (en) 2019-01-03
KR102373215B1 (ko) 2022-03-10
ES2875538T3 (es) 2021-11-10
PT3472314T (pt) 2021-06-18
CN110167575A (zh) 2019-08-23
EP3472314B1 (en) 2021-05-05
IL263591A (en) 2019-02-03
JP2023086970A (ja) 2023-06-22
EP3926044A1 (en) 2021-12-22
DK3472314T3 (da) 2021-07-26
CN116425860A (zh) 2023-07-14
US10954504B2 (en) 2021-03-23
JP7273918B2 (ja) 2023-05-15
EP4588932A2 (en) 2025-07-23
ES3038834T3 (en) 2025-10-15
JP2022000477A (ja) 2022-01-04
EP3472314A4 (en) 2020-01-22
US10604748B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
CL2018003654A1 (es) Preparación de derivados del factor xa.
AR125775A2 (es) Procesador de datos de audio para decodificadores de audio y/o renderizadores y método para procesar datos de audio
WO2020047007A3 (en) Methods for generating spatially barcoded arrays
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EP4621832A3 (en) Methods and systems for measuring periodic structures using multi-angle x-ray reflectance scatterometry (xrs)
WO2014060549A3 (en) Statistical linguistic analysis of source content
CL2020000248A1 (es) Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas.
GB2466172A (en) Microphone array processor based on spatial analysis
BR112018000702A2 (pt) ?processo para preparação de um composto e, uso de um material zeolítico contendo boro?
MX2016012188A (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
MX337382B (es) Metodos para producir nuevos diseños de envases con base en materiales fotoprotectores.
BR112012029919B8 (pt) Processo para preparação de 8-alcóxi [1,2,4] triazolo[1,5-c]pirimidin-2-aminas, substituídas na posição 5, e seus intermediários
SV2016005288A (es) Mã‰todos y aparato para la coordinaciã“n de la selecciã“n del sistema entre un conjunto de nodos
BR112018075185A2 (pt) formulações análogas de hidróxi metionina adequadas para aplicações de produtos químicos especializados
WO2013048899A3 (en) Methods for the on-site production of chloramine and its use thereof
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
MX384158B (es) Método y aparato.
MX2019001453A (es) Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas.
BR112017013256A2 (pt) método de análise, portador de amostra em forma de disco e aplicação de um portador de amostra
BR112017025872A2 (pt) proteínas de ligação multiespecíficas
WO2018013551A8 (en) Tools for next generation komagataella (pichia) engineering
EP4239329A3 (en) Method and apparatus
EA201691510A1 (ru) Новые способы разделения горохового белка
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона